Medgenics has announced that its Israeli-developed INFRADURE Biopump for the treatment of Hepatitis D has received orphan drug status from the US Food and Drug Administration (FDA). This means a faster regulatory process, grants, tax credits and market exclusivity.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000759045&fid=1725
USA gives priority to Israeli hepatitis D treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.